Organogenesis Q3 revenue drops 70% to $45.5 million; net loss $29.6 million
Organogenesis reported third quarter 2026 net product revenue of $45.5 million, down 70% from $150.5 million a year earlier, and a net loss of $29.6 million, compared with net income of $21.6 million in the prior-year quarter. The company also updated its full-year 2026 revenue outlook to $179.4 million to $200.0 million, a decline of 65% to 68%, which it said reflects a more measured fourth-quarter recovery than its prior guidance assumed.
Key points
- Net product revenue was $45.5 million for the quarter ended September 30, 2026, versus $150.5 million a year earlier; Advanced Wound Care fell 73% to $38.2 million.
- Net loss was $29.6 million, or $(0.25) per share, versus net income of $21.6 million, or $0.11 per share, in the third quarter of 2025.
- As of September 30, 2026, cash, cash equivalents and restricted cash totaled $26.9 million, with no outstanding debt obligations.
- Full-year 2026 net revenue guidance is $179.4 million to $200.0 million, versus $564.2 million in 2025.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.